Significant changes may be on the horizon resulting from a pending decision by the DEA to reschedule cannabis to a Schedule 3 substance. The DEA has never rejected a recommendation from the U.S. Department of Health and Human Services, so assuming this recommended rescheduling occurs, this will have a massive impact on the cannabis industry. Join us for a comprehensive exploration of the potential impact on accounting, taxation, mergers and acquisitions, startup ventures, and exits within the cannabis sector.

Learning Objectives:

• Define the concept of cannabis rescheduling and its regulatory implications


• Identify the anticipated effects on industry valuations following the potential rescheduling


• Recognize the specific adjustments required in accounting, taxation, and financial practices post-rescheduling


• Determine the strategic considerations for Mergers and Acquisitions (M&A) activities, startups, and exit strategies within the cannabis industry